321 related articles for article (PubMed ID: 28684785)
1. Identification of Histamine H
Frandsen IO; Boesgaard MW; Fidom K; Hauser AS; Isberg V; Bräuner-Osborne H; Wellendorph P; Gloriam DE
Sci Rep; 2017 Jul; 7(1):4829. PubMed ID: 28684785
[TBL] [Abstract][Full Text] [Related]
2. Generation of a homology model of the human histamine H(3) receptor for ligand docking and pharmacophore-based screening.
Schlegel B; Laggner C; Meier R; Langer T; Schnell D; Seifert R; Stark H; Höltje HD; Sippl W
J Comput Aided Mol Des; 2007 Aug; 21(8):437-53. PubMed ID: 17668276
[TBL] [Abstract][Full Text] [Related]
3. A qualitative model for the histamine H3 receptor explaining agonistic and antagonistic activity simultaneously.
de Esch IJ; Timmerman H; Menge WM; Nederkoorn PH
Arch Pharm (Weinheim); 2000 Aug; 333(8):254-60. PubMed ID: 11008375
[TBL] [Abstract][Full Text] [Related]
4. Function-specific virtual screening for GPCR ligands using a combined scoring method.
Kooistra AJ; Vischer HF; McNaught-Flores D; Leurs R; de Esch IJ; de Graaf C
Sci Rep; 2016 Jun; 6():28288. PubMed ID: 27339552
[TBL] [Abstract][Full Text] [Related]
5. Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore.
Axe FU; Bembenek SD; Szalma S
J Mol Graph Model; 2006 May; 24(6):456-64. PubMed ID: 16386444
[TBL] [Abstract][Full Text] [Related]
6. Detection of multiple H3 receptor affinity states utilizing [3H]A-349821, a novel, selective, non-imidazole histamine H3 receptor inverse agonist radioligand.
Witte DG; Yao BB; Miller TR; Carr TL; Cassar S; Sharma R; Faghih R; Surber BW; Esbenshade TA; Hancock AA; Krueger KM
Br J Pharmacol; 2006 Jul; 148(5):657-70. PubMed ID: 16715122
[TBL] [Abstract][Full Text] [Related]
7. Histamine H
Ghamari N; Zarei O; Reiner D; Dastmalchi S; Stark H; Hamzeh-Mivehroud M
Chem Biol Drug Des; 2019 May; 93(5):832-843. PubMed ID: 30586225
[TBL] [Abstract][Full Text] [Related]
8. Covalent Inhibition of the Histamine H
Wágner G; Mocking TAM; Kooistra AJ; Slynko I; Ábrányi-Balogh P; Keserű GM; Wijtmans M; Vischer HF; de Esch IJP; Leurs R
Molecules; 2019 Dec; 24(24):. PubMed ID: 31835873
[TBL] [Abstract][Full Text] [Related]
9. Ligand-guided homology modeling drives identification of novel histamine H3 receptor ligands.
Schaller D; Hagenow S; Stark H; Wolber G
PLoS One; 2019; 14(6):e0218820. PubMed ID: 31237914
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
Kovalainen JT; Christiaans JA; Kotisaari S; Laitinen JT; Männistö PT; Tuomisto L; Gynther J
J Med Chem; 1999 Apr; 42(7):1193-202. PubMed ID: 10197963
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel lead in the group of N-substituted piperazine ether derivatives with potential histamine H3 receptor activity.
Kuder KJ; Stachnik M; Schunack W; Szymańska E; Kieć-Kononowicz K
Med Chem; 2014; 10(6):588-99. PubMed ID: 24047214
[TBL] [Abstract][Full Text] [Related]
12. Virtual fragment screening: discovery of histamine H3 receptor ligands using ligand-based and protein-based molecular fingerprints.
Sirci F; Istyastono EP; Vischer HF; Kooistra AJ; Nijmeijer S; Kuijer M; Wijtmans M; Mannhold R; Leurs R; de Esch IJ; de Graaf C
J Chem Inf Model; 2012 Dec; 52(12):3308-24. PubMed ID: 23140085
[TBL] [Abstract][Full Text] [Related]
13. Generation of cell lines for drug discovery through random activation of gene expression: application to the human histamine H3 receptor.
Song J; Doucette C; Hanniford D; Hunady K; Wang N; Sherf B; Harrington JJ; Brunden KR; Stricker-Krongrad A
Assay Drug Dev Technol; 2005 Jun; 3(3):309-18. PubMed ID: 15971992
[TBL] [Abstract][Full Text] [Related]
14. Model of a specific human histamine H3 receptor (hH3R) binding pocket suitable for virtual drug design.
Schlegel B; Stark H; Sippl W; Höltje HD
Inflamm Res; 2005 Apr; 54 Suppl 1():S50-1. PubMed ID: 15928832
[No Abstract] [Full Text] [Related]
15. The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists.
Hancock AA
Biochem Pharmacol; 2006 Apr; 71(8):1103-13. PubMed ID: 16513092
[TBL] [Abstract][Full Text] [Related]
16. Ligand binding kinetics at histamine H
Reiner D; Stark H
Eur J Pharmacol; 2019 Apr; 848():112-120. PubMed ID: 30703360
[TBL] [Abstract][Full Text] [Related]
17. Novel and highly potent histamine H3 receptor ligands. Part 3: an alcohol function to improve the pharmacokinetic profile.
Labeeuw O; Levoin N; Poupardin-Olivier O; Calmels T; Ligneau X; Berrebi-Bertrand I; Robert P; Lecomte JM; Schwartz JC; Capet M
Bioorg Med Chem Lett; 2013 May; 23(9):2548-54. PubMed ID: 23535326
[TBL] [Abstract][Full Text] [Related]
18. A new class of histamine H3 receptor antagonists derived from ligand based design.
Roche O; Rodríguez Sarmiento RM
Bioorg Med Chem Lett; 2007 Jul; 17(13):3670-5. PubMed ID: 17498953
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists.
Kitbunnadaj R; Zuiderveld OP; De Esch IJ; Vollinga RC; Bakker R; Lutz M; Spek AL; Cavoy E; Deltent MF; Menge WM; Timmerman H; Leurs R
J Med Chem; 2003 Dec; 46(25):5445-57. PubMed ID: 14640553
[TBL] [Abstract][Full Text] [Related]
20. A new crystal structure fragment-based pharmacophore method for G protein-coupled receptors.
Fidom K; Isberg V; Hauser AS; Mordalski S; Lehto T; Bojarski AJ; Gloriam DE
Methods; 2015 Jan; 71():104-12. PubMed ID: 25286328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
